COPENHAGEN (Reuters) – Diabetes drug manufacturer Novo Nordisk will initiate a late-stage trial to investigate the benefits of its semaglutide drug in treatment of Alzheimer’s disease, the company said on Wednesday.
“Due to the growing unmet medical need and the increasing evidence of a potential therapeutic role for GLP-1, we will investigate the benefits of oral semaglutide in early Alzheimer’s disease,” Chief Scientific Officer Mads Krogsgaard said in a statement.
The phase 3a trial is set to start in the first half of 2021 and include about 3,700 people, Novo said.
(Reporting by Nikolaj Skydsgaard; Editing by David Goodman)
